Impact of maternal desvenlafaxine exposure on brain development in pregnant albino rats and their fetuses
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.23062
Abstract: Depression during pregnancy adversely affects fetal development. Desvenlafaxine drug is used for the treatment of gestational depression. In light of the well‐established role of brain‐derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in regulating… read more here.
Keywords: desvenlafaxine; brain development; maternal fetal; brain ... See more keywords
Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Toxicology"
DOI: 10.1080/15563650.2016.1223847
Abstract: Abstract Context: Desvenlafaxine is used to treat major depression. Desvenlafaxine is also the active metabolite of venlafaxine. Venlafaxine overdose can cause serotonin toxicity, seizures and cardiovascular effects, but there is limited information on desvenlafaxine overdose.… read more here.
Keywords: desvenlafaxine overdose; desvenlafaxine; serotonin toxicity; toxicity seizures ... See more keywords
False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Case Reports"
DOI: 10.1136/bcr-2017-222106
Abstract: We report a likely false-positive phencyclidine (PCP) result detected with a urine drug screen (UDS) (Medtox, St Paul, Minnesota, USA) in the setting of therapeutic desvenlafaxine (Pristiq) use. Desvenlafaxine (O-desmethylvenlafaxine) is the active metabolite of… read more here.
Keywords: desvenlafaxine; use; phencyclidine pcp; false positive ... See more keywords
Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1110460
Abstract: Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic information is available nowadays concerning desvenlafaxine, its active metabolite first marketed in 2012. The aim… read more here.
Keywords: desvenlafaxine; impact polymorphisms; adr; pharmacokinetic variability ... See more keywords